Advertisement
DRUG vs PTHS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a StrongBuy and PTHS is a Hold.
DRUG sees its Stochastic Oscillator ascends from oversold territory
On October 27, 2026, the Stochastic Oscillator for DRUG moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In 55 of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for DRUG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +4.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRUG advanced for three days, in 155 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
DRUG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DRUG as a result. In 88 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DRUG turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRUG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DRUG entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.687) is normal, around the industry mean (3.104). P/E Ratio (-7.588) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. DRUG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRUG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PTHS's Stochastic Oscillator is sitting in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PTHS's RSI Oscillator exited the oversold zone, 9 of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +14.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTHS advanced for three days, in 107 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PTHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTHS as a result. In 40 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for PTHS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In 25 of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PTHS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-29.383) is normal, around the industry mean (3.104). P/E Ratio (-0.402) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (1.470) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. PTHS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| DRUG | PTHS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 82% | 6 days ago 79% |
| Declines ODDS (%) | 2 days ago 90% | 8 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRUG’s FA Score shows that 2 FA rating(s) are green while PTHS’s FA Score has 2 green FA rating(s).
- DRUG’s FA Score: 2 green, 3 red.
- PTHS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRUG’s TA Score shows that 4 TA indicator(s) are bullish while PTHS’s TA Score has 4 bullish TA indicator(s).
- DRUG’s TA Score: 4 bullish, 4 bearish.
- PTHS’s TA Score: 4 bullish, 4 bearish.
Price Growth
DRUG (@Biotechnology) experienced а -60.11% price change this week, while PTHS (@Biotechnology) price change was -25.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.
Reported Earning Dates
DRUG is expected to report earnings on Dec 22, 2026.
PTHS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-2.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DRUG and
Correlation & Price change
A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with KPTI. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then KPTI could also see price increases.
| Ticker / NAME | Correlation To DRUG | 1D Price Change % | ||
|---|---|---|---|---|
| DRUG | 100% | -17.75% | ||
| KPTI - DRUG | 59% Loosely correlated | -21.16% | ||
| PTHS - DRUG | 46% Loosely correlated | -6.42% | ||
| PGEN - DRUG | 40% Loosely correlated | +2.14% | ||
| MDXG - DRUG | 40% Loosely correlated | -0.91% | ||
| IMVT - DRUG | 39% Loosely correlated | +2.22% | ||
More | ||||
PTHS and
Correlation & Price change
A.I.dvisor indicates that over the last year, PTHS has been loosely correlated with DRUG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PTHS jumps, then DRUG could also see price increases.
| Ticker / NAME | Correlation To PTHS | 1D Price Change % | ||
|---|---|---|---|---|
| PTHS | 100% | -6.42% | ||
| DRUG - PTHS | 46% Loosely correlated | -17.75% | ||
| KLRS - PTHS | 43% Loosely correlated | +2.50% | ||
| KPTI - PTHS | 39% Loosely correlated | -21.16% | ||
| PASG - PTHS | 38% Loosely correlated | +2.41% | ||
| INKT - PTHS | 36% Loosely correlated | +1.51% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GDXD | 30.52 | 1.73 | +6.01% |
| MicroSectors Gold Miners - 3X Inverse Leveraged ETNs (GDXD) | |||
| IXN | 133.13 | 1.65 | +1.25% |
| iShares Global Tech ETF (IXN) | |||
| DWWN | 23.82 | N/A | N/A |
| Principal Long Duration ETF (DWWN) | |||
| BBSB | 97.40 | -0.07 | -0.08% |
| JPMorgan BetaBuilders U.S. Treasury Bond 1-3 Year ETF (BBSB) | |||
| CPER | 38.51 | -0.86 | -2.18% |
| United States Copper Index Fund (CPER) | |||